Potassium citrate mixture

Pajjiż: Ingilterra

Lingwa: Ingliż

Sors: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredjent attiv:

Potassium citrate; Citric acid monohydrate

Disponibbli minn:

Thornton & Ross Ltd

Kodiċi ATC:

A12BA02

INN (Isem Internazzjonali):

Potassium citrate; Citric acid monohydrate

Dożaġġ:

300mg/1ml ; 50mg/1ml

Għamla farmaċewtika:

Oral solution

Rotta amministrattiva:

Oral

Klassi:

No Controlled Drug Status

Tip ta 'preskrizzjoni:

Valid as a prescribable product

Sommarju tal-prodott:

BNF: 07040300; GTIN: 5011309030112

Fuljett ta 'informazzjoni

POTASSIUM CITRATE MIXTURE

Karatteristiċi tal-prodott

OBJECT 1
POTASSIUM CITRATE MIXTURE
Summary of Product Characteristics Updated 09-Nov-2020 | Thornton &
Ross Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Potassium Citrate Mixture
2. Qualitative and quantitative composition
Potassium Citrate 1.5g/5ml.
Excipients with known effects
Sucrose 1.1g/5ml
Sodium benzoate (E211) 2.5mg/5ml
Ethanol 0.02mg/5ml
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Solution
4. Clinical particulars
4.1 Therapeutic indications
For the symptomatic relief of dysuria associated with mild urinary
tract infections, especially cystitis.
Indications stated on label: For the relief of the symptoms of
cystitis and other mild urinary tract
infections.
4.2 Posology and method of administration
Oral:
Recommended Doses
Unless directed otherwise by a doctor:
Adults including the elderly, and children over 6 years: 10ml.
Children 1 - 6 years: 5ml.
It should be taken well diluted with water, after meals.
Shake the bottle before